Rein Therapeutics Inc (RNTX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access RNTX quarterly Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Rein Therapeutics Inc funds operations, investments, and shareholder returns.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
12 Months
(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-49.87
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)28.70
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation2.22
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Increase Decrease In Operating Lease Liabilities-0.05
Commitment Fee Related To Pre- Paid Advance Agreement-
Original Issue Discount Related To Pre- Paid Advance Agreement-
Income taxes-0.71
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable3.07
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-2.62
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.32
Other Working Capital-0.99
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-19.36
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock3.42
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.48
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Initial Public Offering Of Common Stock Net Of Offering Costs-
Payments For Proceeds From Issuance Of Redeemable Convertible Preferred Stock-
Proceeds From Issuance Of Common Stock Common Warrants And Pre Funded Warrants Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations17.34
Proceeds From Issuance Of Common Stock And Common Warrants And Pre Funded Warrants Net Of Issuance Costs-
Proceeds From Paycheck Protection Program Loan-
Proceeds From Issuance Of Common Stock Net Of Issuance Costs-
Proceeds From Financing-
Proceeds From P I P E Financing-
Proceeds From Warrant Exchanges-
Proceeds From Warrant Exercises With Common Stock Subscribed-
Proceeds From Pre- Paid Advances-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities9.76
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-19.36
Total Cash Flow-9.65
4 historic quarters locked

Sign in to unlock the full Rein Therapeutics Inc cash flow history.

About Rein Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-126385

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document





                    
Get the full CSIMarket dataset: Subscribe API License